Skip to main content

Advertisement

SpringerLink
Log in

Low doses of rIL2 after autologous bone marrow transplantation induce a “prolonged” immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Ten patients with high-grade non-HodgKin's lymphoma (HG-NHL) entered a subcutaneous (s.c.) recombinant interleukin 2 (rIL2) trial within 2 months of undergoing autologous bone marrow transplantation (ABMT). Immunological studies, consisting in T- and natural killer (NK)-cell subset assessment, together with functional assays, such as NK activity and CD16-mediated redirected killing assay, were performed before therapy, after 2 weeks, and then monthly. Phenotypic analysis showed a significant increase (p=0.01) of CD16 and CD56 NK cells, from 12% to 28% and from 17% to 37%, respectively. In particular, the CD56bright NK cell population showed a tenfold increase, while CD56dim NK cells remained unmodified compared with pretreatment values. The expression of IL2 receptors was also studied, and a significant increase (p=0.01) of CD122 (p75)-positive cells from 8% to 30% was found, while no significant increase was observed in CD25 (p55)-positive cells. Furthermore, rIL2 administration led to an increase of NK activity even at the lowest effectors: target ratio and to an increase of CD16-mediated redirected killing assay. These phenotypic and functional modifications lasted throughout the duration of rIL2 therapy and remained after completion of therapy. In addition, none of the ten patients relapsed, and two of them who started IL2 treatment while still showing residual disease experienced a complete disappearance of the disease after 10 and 7 months of therapy, respectively. Our data suggest that infusion of rIL2 s.c. after ABMT is safe, can selectively increase NK cell number and function, and may have a beneficial effect on the minimal residual disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Atzpodien J, Korfer A, Evers P, Franks CR, Knuver-Hopf J, Lopez-Hnninen, Fischer M, Mohr H, Dallmann I, Hadam M, Poliwoda H, Kirchner H (1990) Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 2:18–26

    PubMed  Google Scholar 

  2. Ault KA, Antin JH, Ginsburg D, Orkin SH, Rappaport JM, Keohan MN, Martin P, Smith BR (1985) Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med 161:1483–1489

    PubMed  Google Scholar 

  3. Bilgrami S, Silva M, Cardoso A, Miller KB, Ascensao JL (1994) Immunotherapy with autologous bone-marrow transplantation: rationale and results. Exp Haematol 22:1039–1050

    Google Scholar 

  4. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J (1990) Functional consequences of interleukin 2 receptor expression on resting human lymphocytes, identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171:1509–1513

    PubMed  Google Scholar 

  5. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klumpp TR, Soiffer RJ, Smith KA, Ritz J (1993) Selective modulation of human natural killer cells in vivo following prolonged infusion of low-dose recombinant interleukin 2. J Clin Invest 91:123–128

    PubMed  Google Scholar 

  6. Choe B, Frost P, Morrison N, Rose N (1987) Natural killer cell activity of prostatic cancer patients. Cancer Invest 5:285–288

    PubMed  Google Scholar 

  7. Dilloo D, Laws HJ, Hanenberg H, Korholz D, Nurnberger W, Burdach SEG (1994) Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children solid tumors. Exp Haematol 22:1081–1088

    Google Scholar 

  8. Ellis TM, Fisher RI (1989) Functional heterogeneity of Leu19“bright+” and Leu19“dim”+ lymphokine-activated killer cells. J Immunol 142:2949–2954

    PubMed  Google Scholar 

  9. Ellis TM, Creekmore SP, McMannis JD, Braun DP, Harris JA, Fisher RI (1988) Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. Cancer Res 48:6597–6602

    PubMed  Google Scholar 

  10. Foa R, Fierro MT, Tosti S, Meloni G, Gavosto F, Mandelli F (1990) Induction and persistence of complete remission in a resistant acute myeloid leukemia patient following treatment with recombinant interleukin 2. Leuk Lymphoma 1:113–117

    Google Scholar 

  11. Fujimiya Y, Chang W-C, Bakke A, Horwitz D, Pattengale P (1987) Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. Cancer Immunol Immunother 24:213–218

    PubMed  Google Scholar 

  12. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymohokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823–1841

    PubMed  Google Scholar 

  13. Herberman RB, Ortaldo JR (1981) Natural killer cells: their role in defenses against disease. Science 214:24–30

    PubMed  Google Scholar 

  14. Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE (1992) CD16-CD56+ Natural killer cells after bone marrow transplantation. Blood 12:3239–3244

    Google Scholar 

  15. Introna M, Mantovani A (1983) Natural killer cells in human solid tumors. Cancer Metastasis Rev 2:337–340

    PubMed  Google Scholar 

  16. Lanier LL, Phillips JH (1985) A map of the cell surface antigens expressed on resting and activated human natural killer cells. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID (eds) Leukocyte typing II. Springer Berlin Heidelberg New York, p 157

    Google Scholar 

  17. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH (1986) The relationship of CD 16 (Leu-11) and Leu 19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 12:4480–86

    Google Scholar 

  18. Lauria F, Zinzani PL, Rondelli D, Raspadori D, Benfenati D, Tura S (1991) Continuous infusion of interleukin-2 in two relapsed high-grade non-Hodgkin's lymphoma patients: effectiveness and tolerability. Eur J Cancer 27:521–522

    PubMed  Google Scholar 

  19. Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Archili C, Vaghi M, Tancini G (1992) Second-line therapy with low-dose subscutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28:92–99

    PubMed  Google Scholar 

  20. Lotzova E, Savary CA, Herbermann RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138:2718–2727

    PubMed  Google Scholar 

  21. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa AM, Reiffers J, Gratecos N, Berau-Perez P, Mannoni P, Mawas C, Hercend T, Sebahoun G, Carcassonne Y (1991) High-dose recombinant interleukin-2 and acule myeloid leukemias in relapse. Blood 78:2182–2187

    PubMed  Google Scholar 

  22. Nagler A, Lanier LL, Phillips JH (1990) Constitutive expression of high-affinity interleukin 2 receptors on human CD16}-natural killer cells in vivo. J Exp Med 171:1527–1532

    PubMed  Google Scholar 

  23. Niederwieser D, Gastl G, Rumpold H, Marth CH, Kraft D, Huber CH (1987) Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer activity after human bone marrow transplantation (BMT). Br J Haematol 65:301–308

    PubMed  Google Scholar 

  24. Ortaldo JR, Sharrow So, Timonen T, Herberman RB (1981) Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol 127:2401–2407

    PubMed  Google Scholar 

  25. Reittie JE, Gottlieb DJ, Heslop HE, Leger O, Hazlehurst G, Drexler HG, Hoffbrand AV, Prentice HG, Brenner MK (1989) Endogenously generated activated killer cells circulate after autologous and allogeneic bone marrow transplantation. Blood 73:1351–1358

    PubMed  Google Scholar 

  26. Rooney CM, Wimperis JZ, Brenner MK, Patterson J, Offbrand AV, Prentice HG (1986) Natural killer cell activity following T-cell-depleted allogeneic bone marrow transplantation. Br J Haematol 62:413–418

    PubMed  Google Scholar 

  27. Rosenberg SA, Lotze MD, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng J Med 313:1485–1492

    Google Scholar 

  28. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwaz S (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant IL-2. J Exp Med 161:1169–1190

    PubMed  Google Scholar 

  29. Soiffer RJ, Murray C, Gonin R, Ritz J (1994) Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964–971

    PubMed  Google Scholar 

  30. Stein RC, Malkovska V, Morgan S, Galazka A, Aniszewski C, Roy SE, Shearer RJ, Marsden RA, Bevan D, Gordon-Smith EC, Coombes RC (1991) The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin 2. Br J Cancer 63:275–282

    PubMed  Google Scholar 

  31. Timonen T, Ortaldo JR, Herberman RB (1981) Characteristics of human large granular lymphocytes and their relationship to natural killer and k cells. J Exp Med 153:569–582

    PubMed  Google Scholar 

  32. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurnam GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905

    PubMed  Google Scholar 

  33. Zarling JM, Clouse KA, Biddison WE, Kung PC (1981) Phenotype of human natural killer cell populations detected with monoclonal antibodies. J Immunol 127:2575–2581

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Hematology “L. e A. Seràgnoli”, Via Massarenti 9, I-40138, Bologna, Italy

    D. Raspadori, M. A. Ventura, M. C. Miggiano, D. Rondelli & S. Tura

  2. Institute of Medical Science, University of Milan, Milan, Italy

    F. Lauria

  3. Department of Immunohematology and Transfusion, Policlinico S. Orsola, Bologna, Italy

    P. L. Tazzari

  4. Department of Pharmacology, National Institute for Cancer Research (IST), Genoa, Italy

    S. Ferrini

Authors
  1. D. Raspadori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Lauria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Ventura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. L. Tazzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Ferrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. C. Miggiano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Rondelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Tura
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work sas supported in part by CNR PF ACRO: 94.01214.PF39.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raspadori, D., Lauria, F., Ventura, M.A. et al. Low doses of rIL2 after autologous bone marrow transplantation induce a “prolonged” immunostimulation of NK compartment in high-grade non-Hodgkin's lymphomas. Ann Hematol 71, 175–179 (1995). https://doi.org/10.1007/BF01910314

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01910314

Key words

Search

Navigation